Profile of ipilimumab and its role in the treatment of metastatic melanoma
Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechani...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2011-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1a13f764a74041a68cdd688d6be514e8 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Patel SP |e author |
| 700 | 1 | 0 | |a Woodman SE |e author |
| 245 | 0 | 0 | |a Profile of ipilimumab and its role in the treatment of metastatic melanoma |
| 260 | |b Dove Medical Press, |c 2011-12-01T00:00:00Z. | ||
| 500 | |a 1177-8881 | ||
| 520 | |a Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms. Multiple immune-modulatory therapies are currently being developed to optimize the immune response to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell activation, have demonstrated improvement in overall survival of metastatic melanoma patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, the immune-related response criteria used to evaluate clinical response, and side-effect profile associated with ipilimumab treatment.Keywords: ipilimumab, melanoma, T-cells, CTLA-4 | ||
| 546 | |a EN | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drug Design, Development and Therapy, Vol 2011, Iss default, Pp 489-495 (2011) | |
| 787 | 0 | |n http://www.dovepress.com/profile-of-ipilimumab-and-its-role-in-the-treatment-of-metastatic-mela-a8882 | |
| 787 | 0 | |n https://doaj.org/toc/1177-8881 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1a13f764a74041a68cdd688d6be514e8 |z Connect to this object online. |